Gold, Ralf
Piani-Meier, Daniela
Kappos, Ludwig
Bar-Or, Amit
Vermersch, Patrick
Giovannoni, Gavin
Fox, Robert J.
Arnold, Douglas L.
Benedict, Ralph H. B.
Penner, Iris-Katharina
Rouyrre, Nicolas
Kilaru, Ajay
Karlsson, Göril
Ritter, Shannon
Dahlke, Frank
Hach, Thomas
Cree, Bruce A. C.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
https://doi.org/10.1007/s00415-022-11166-z
Funding for this research was provided by:
Novartis Pharma
Ruhr-Universität Bochum
Article History
Received: 24 August 2021
Revised: 29 April 2022
Accepted: 1 May 2022
First Online: 31 May 2022
Declarations
:
: R. Gold has received compensation for serving as a consultant or speaker from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis and Teva Neuroscience; and he or the institution he works for has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis and Teva Neuroscience; he has also received fees for service as a journal editor from SAGE and Thieme Verlag. L. Kappos’ institution (University Hospital Basel) has received steering committee, advisory board and consultancy fees used exclusively for research support in the department, as well as support of educational activities, from Actelion, Allergan, Almirall, Baxalta, Bayer, Biogen, Celgene/Receptos, CSL-Behring, Desitin, Eisai, Excemed, F. Hoffmann-La Roche Ltd, Genzyme, Japan Tobacco, Merck, Minoryx, Novartis, Pfizer, Sanofi Aventis, Santhera and Teva; and license fees for Neurostatus-UHB products. Research at the MS Center in Basel has been supported by grants from Bayer, Biogen, the European Union, Inno-Suisse, Novartis, Roche, the Swiss MS Society and the Swiss National Research Foundation. A. Bar-Or has participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme. P. Vermersch has received fees for service and consulting fees from AB Science, Biogen, Celgene, Imcyse, Merck, Novartis, Roche, Sanofi Genzyme and Teva, and research support from Novartis, Roche and Sanofi Genzyme. G. Giovannoni has received compensation for serving as a consultant or speaker for or has received research support from AbbVie, Aslan, Atara Bio, Biogen, BMS-Celgene, GlaxoSmithKline, GW Pharma, Janssens/Actelion, Japanese Tobacco, Jazz Pharmaceuticals, LifNano, Merck & Co, Merck KGaA/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme and Teva. R. J. Fox has received personal fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis and Teva; grants from Novartis; and other support from Biogen and Novartis (clinical trial contracts). D. L. Arnold has received personal fees from Acorda, Albert Charitable Trust, Biogen, Celgene, Frequency Therapeutics, GeNeuro, MedDay, Merck Serono, Novartis, Roche, Sanofi Aventis and Wave Life Sciences; grants from Biogen, Immunotec and Novartis; and has equity interest in NeuroRx, outside the submitted work. R. H. B. Benedict reports research support and grants from Biogen, Genentech, Genzyme, Mallinkrodt, National MS Society and the NIH; he has consulting or speaking relationships with Biogen, EMD Serono, Genzyme, Novartis, Roche, Sanofi and Verasci; and he receives royalties from Psychological Assessment Resources, Inc. I.-K. Penner has received fees for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from Adamas Pharma, Almirall, Bayer Pharma, Biogen, Celgene, Desitin, Genzyme, Merck, Novartis, Roche and Teva. She has received research support from Celgene, the German MS Society, Novartis and Teva. N. Rouyrre, A. Kilaru, G. Karlsson, S. Ritter, D. Piani-Meier and T. Hach are employees of Novartis. F. Dahlke was an employee of Novartis at the time of writing. B. A. C. Cree has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, EMD Serono, Novartis, Sanofi, TG Therapeutics and Therini; and research support from Genentech.
: All authors had full access to all the data in the study, and the corresponding author had final responsibility for the decision to submit for publication.